ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2558

The Role of Leukocyte Associated Immunoglobulin-like Receptor-1 (LAIR-1) in Collagen-Induced Arthritis

Seunghyun Kim1, John E. Coligan2, Jeoung-Eun Park3, John M. Stuart4, Andrew Kang5 and Linda Myers5, 1Rheumatology, University of Tennessee Health Science Center, Memphis, TN, 2NIH, Bethesda, MD, 3University of Tennessee, Memphis, TN, 4University of Tennessee/Veterans Affairs, Memphis, TN, 5University of Tennessee Health Science Center, Memphis, TN

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Animal models

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Animal Models Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Several observations implicate a critical role for T cell dysregulation as a central problem in RA.  We present a method for suppressing T cell activation by activating natural inhibitory receptors called leukocyte associated immunoglobulin-like receptor-1 (LAIR-1).  We used the collagen-induced arthritis model and DR-1 tg mice to study the importance of LAIR-1 in autoimmune arthritis.

Methods: a.) Murine splenocytes (LAIR-1 +/+ or LAIR-1 -/-) were stimulated with soluble CD3 in the presence or absence of collagen and supernatants were collected for cytokine analysis.  b.) DR-1 mice were immunized with CII/CFA to induce arthritis and were injected intra-articularly with 0.3mg of either the stimulatory monoclonal antibody to LAIR-1 or a hamster IgG control.  c.) DR1/LAIR-1 -/- and DR1/LAIR-1 +/+ mice were immunized to induce arthritis and mean severity scores were recorded thrice weekly.

Results: a.) In the presence of LAIR-1, CD3-induced cytokine secretion was significantly suppressed in the presence of collagen, while LAIR-1 -/- cells had no attenuation.  b.) Treatment with the stimulatory monoclonal antibody to LAIR-1 attenuated CIA in the mice (severity scores 1.5 ± 1.9 vs. 6.4 ± 2.4, p = 0.007).   c.) DR1/LAIR-1-/- mice that were immunized with CII developed more severe arthritis and had a greater percentage of limbs affected with arthritis than did the wild type (DR1/LAIR-1 +/+) group (p<0.05). 

Conclusion: Taken together, these data demonstrate that collagen can suppress T cell cytokine response in the presence of LAIR-1.  Treatment with stimulating mLAIR-1 antibodies suppresses CIA while DR1/LAIR-1 -/- mice develop more severe arthritis than wild type controls.  These data suggest that LAIR-1 may be a potential therapeutic target for suppressing RA.


Disclosure: S. Kim, None; J. E. Coligan, None; J. E. Park, None; J. M. Stuart, None; A. Kang, None; L. Myers, None.

To cite this abstract in AMA style:

Kim S, Coligan JE, Park JE, Stuart JM, Kang A, Myers L. The Role of Leukocyte Associated Immunoglobulin-like Receptor-1 (LAIR-1) in Collagen-Induced Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-role-of-leukocyte-associated-immunoglobulin-like-receptor-1-lair-1-in-collagen-induced-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-role-of-leukocyte-associated-immunoglobulin-like-receptor-1-lair-1-in-collagen-induced-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology